Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ACRV
ACRIVON THERAPEUTICS, INC. COMMON STOCK
NASDAQ
$2.06
▼ DOWN 4.19% (-0.09)

KEY STATISTICS

Market Cap$88.17 M
52w High$3.56
52w Low$1.27
Dividend Yield—
Frequency—
P/E-1.10
Volume217.12K
Shares Out.42.80M

COMPANY

LEADERSHIP

Peter Blume-Jensen
CHIEF EXECUTIVE
Peter Blume-Jensen

COMPENSATION 2026

Salary$709,893
Stock Awards$0
Incentive Plan Pay$410,400
All Other Comp.$6,000
Total$2,718,538

ABOUT

SECTOR
Healthcare
WENT PUBLIC
November 15, 2022
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
75

PRICE TARGET

Target High$30.00
Target Low$17.00
Target Median$20.00
Target Consensus$21.83

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.$504.33K
NOV
12
THU

PRICE

$2.06 ▼ DOWN 4.19% (−$0.09)
$2.07$2.10$2.139:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM2.06

About Acrivon Therapeutics, Inc. Common Stock

https://www.acrivon.com ↗

Acrivon Therapeutics is a clinical-stage biotech developing targeted oncology medicines using proteomics-based diagnostics, with lead candidate ACR-368 in Phase 2 for various tumors.

INDUSTRY

Biotechnology

A PRODUCT ACRIVON THERAPEUTICS, INC. COMMON STOCK IS KNOWN FOR

ACR-368 (prexasertib)
ACR-368 (prexasertib)

ACR-368, Acrivon's lead Phase 2 drug candidate targeting CHK1/2 kinases for solid tumors, especially endometrial and ovarian cancers, has FDA Fast Track status and an OncoSignature test to identify responsive patients.

COMPETITORS

COMPETITOR
APRE COMPARE
AZN COMPARE
BOLD COMPARE
ZNTL COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
11
LISTED HERE
2
RANKED BY POSITION SIZE
VTS.AX
0.00% · 545.5K
IWC
0.01% · 74.8K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
42.75%
HOLDERS
64
TOP 12 OF 64 · RANKED BY POSITION SIZE
Ra Capital Management, L.P.
8.3M sh · $11.59M
Sands Capital Ventures, LLC
2.1M sh · $2.95M
Citadel Advisors LLC
1.6M sh · $3.96M
Wellington Management Group Llp
888.1K sh · $1.23M
Acadian Asset Management LLC
846.0K sh · $1.18M
Blackrock Inc.
767.0K sh · $4.45M
Renaissance Technologies LLC
758.4K sh · $1.05M
Vanguard Group Inc
698.9K sh · $1.68M
Ubs Group AG
683.2K sh · $1.24M
Two Sigma Investments, LP
585.1K sh · $1.41M
Marshall Wace, Llp
560.4K sh · $779.01K
Acorn Capital Advisors, LLC
405.2K sh · $733.48K

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book4
Overall Score2

INSIDER TRADES

★
DIRECTOR, OFFICER: PRESIDENT AND CEO
Blume-Jensen Peter
Sale · 14.0K shares
2026-08-25
★
OFFICER: CHIEF LEGAL OFFICER
Miller Mary
Sale · 185 shares
2026-08-18
★
OFFICER: CHIEF DEVELOPMENT OFFICER
Gamelin Erick
Sale · 400 shares
2026-08-18
★
OFFICER: CHIEF OPERATING OFFICER
Devroe Eric
Sale · 604 shares
2026-08-18

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OVERWEIGHT 1
BUY 1
2 GRADES IN THE LAST 12 MONTHS
Piper Sandler OVERWEIGHT HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
RLMD$4.33COMPARE
IMUX$15.40COMPARE
UNCY$5.26COMPARE
CBUS$1.65COMPARE
BMEA$1.73COMPARE
VXRT$0.50COMPARE
PMVP$1.22COMPARE
ATYR$0.54COMPARE